These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 39018058)

  • 21. Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.
    Simpson EL; Blauvelt A; Silverberg JI; Cork MJ; Katoh N; Mark T; Schneider SKR; Wollenberg A
    Am J Clin Dermatol; 2024 Jan; 25(1):139-148. PubMed ID: 37804473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis.
    Silverberg JI; Hong HC; Calimlim BM; Lee WJ; Teixeira HD; Collins EB; Crowell MM; Johnson SJ; Armstrong AW
    Dermatol Ther (Heidelb); 2023 Oct; 13(10):2247-2264. PubMed ID: 37658223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Placebo responses in randomized controlled trials for systemic therapy in atopic dermatitis: A systematic review and meta-analysis.
    Lee HH; Patel KR; Rastogi S; Singam V; Vakharia PP; Chopra R; Silverberg JI
    J Am Acad Dermatol; 2020 Jan; 82(1):62-71. PubMed ID: 31202874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phototherapy for atopic eczema.
    Musters AH; Mashayekhi S; Harvey J; Axon E; Lax SJ; Flohr C; Drucker AM; Gerbens L; Ferguson J; Ibbotson S; Dawe RS; Garritsen F; Brouwer M; Limpens J; Prescott LE; Boyle RJ; Spuls PI
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013870. PubMed ID: 34709669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching between JAK Inhibitors in Patients with Atopic Dermatitis: Unanswered Questions in Daily Clinical Practice.
    Mastraftsi S; Bakakis M; Tsiogka A; Afroditi Kleidona I; Gregoriou S
    Acta Dermatovenerol Croat; 2023 Dec; 31(3):162-164. PubMed ID: 38439732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescent patients: a systematic review.
    Zheng Y; Ding RL; Bu J
    Front Immunol; 2024; 15():1367099. PubMed ID: 38812522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.
    Chiricozzi A; Ortoncelli M; Schena D; Gori N; Ferrucci SM; Babino G; Napolitano M; Fargnoli MC; Stingeni L; Rossi M; Romanelli M; Balestri R; Pellegrino M; Parodi A; Bertoldi AM; Palazzo G; Antonelli F; Pitino A; Tripepi G; Fabbrocini G; Balato A; Marzano AV; Girolomoni G; Ribero S; Peris K
    Am J Clin Dermatol; 2023 Nov; 24(6):953-961. PubMed ID: 37322324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2).
    Simpson E; Fernández-Peñas P; de Bruin-Weller M; Lio PA; Chu CY; Ezzedine K; Agell H; Casillas M; Ding Y; Yang FE; Pierce E; Bieber T
    Adv Ther; 2024 Sep; ():. PubMed ID: 39249591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topical tacrolimus for atopic dermatitis.
    Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
    Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register.
    Alexander H; Malek R; Prieto-Merino D; Gribaleva E; Baden M; Beattie P; Brown S; Burton T; Cameron S; Coker B; Cork MJ; Hearn R; Ingram JR; Irvine AD; Johnston GA; Lambert A; Lunt M; Man I; Newell L; Ogg G; Patel P; Wan M; Warren RB; Woolf R; Yiu ZZN; Reynolds N; Ardern-Jones MR; Flohr C
    Br J Dermatol; 2024 Nov; 191(6):988-999. PubMed ID: 39044673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
    Blauvelt A; Teixeira HD; Simpson EL; Costanzo A; De Bruin-Weller M; Barbarot S; Prajapati VH; Lio P; Hu X; Wu T; Liu J; Ladizinski B; Chu AD; Eyerich K
    JAMA Dermatol; 2021 Sep; 157(9):1047-1055. PubMed ID: 34347860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of abrocitinib for the treatment of adolescents and adults with moderate-to-severe atopic dermatitis: update of a living systematic review and meta-analysis.
    Zheng H; Chen Y; Xu Y; Deng X
    Eur J Dermatol; 2023 Oct; 33(5):530-543. PubMed ID: 38297930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
    Reich K; Thyssen JP; Blauvelt A; Eyerich K; Soong W; Rice ZP; Hong HC; Katoh N; Valenzuela F; DiBonaventura M; Bratt TA; Zhang F; Clibborn C; Rojo R; Valdez H; Kerkmann U
    Lancet; 2022 Jul; 400(10348):273-282. PubMed ID: 35871814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2022 May; 5(5):CD011535. PubMed ID: 35603936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis.
    Snast I; Reiter O; Hodak E; Friedland R; Mimouni D; Leshem YA
    Am J Clin Dermatol; 2018 Apr; 19(2):145-165. PubMed ID: 29098604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific allergen immunotherapy for the treatment of atopic eczema.
    Tam H; Calderon MA; Manikam L; Nankervis H; García Núñez I; Williams HC; Durham S; Boyle RJ
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008774. PubMed ID: 26871981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
    Silverberg JI; Simpson EL; Thyssen JP; Gooderham M; Chan G; Feeney C; Biswas P; Valdez H; DiBonaventura M; Nduaka C; Rojo R
    JAMA Dermatol; 2020 Aug; 156(8):863-873. PubMed ID: 32492087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24.
    Offidani A; Stingeni L; Neri I; Cipriani F; Chen Z; Rossi AB; Lu Y; Moretti D
    Ital J Dermatol Venerol; 2022 Feb; 157(1):39-46. PubMed ID: 33878856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis.
    Alves C; Penedones A; Mendes D; Batel Marques F
    Eur J Clin Pharmacol; 2022 Dec; 78(12):1923-1933. PubMed ID: 36207461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.